Evaluating Tarlatamab as a Treatment for Recurrent Small-Cell Lung Cancer
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on November 15th, 2023
|
Small-cell lung cancer is known for its aggressive nature and tendency to recur even after initial treatment. Secondary therapy options are limited, with existing treatments demonstrating relatively low effectiveness. Tarlatamab, a bispecific T-cell engager, works by enhancing the detection of cancer cells expressing DLL-3 by the patient's T-cells, thereby increasing the likelihood of destroying these cancer cells. Amgen, a pharmaceutical company, sponsored a study to evaluate the effectiveness of Tarlatamab as a treatment for small-cell lung cancer.
The phase 2 clinical trial enrolled 220 patients previously diagnosed with small-cell lung cancer that had relapsed following initial platinum-based chemotherapy, with approximately 95% of these patients experiencing metastasis. Participants were randomly assigned to receive two doses of Tarlatamab - 10 mg versus 100 mg - administered intravenously every two weeks. After a median 10-month follow-up period, researchers observed a tumor size reduction in around 40% of patients, with an estimated 9-month survival rate of approximately 65%. Comparing the two doses, there was little difference in effectiveness, but considering safety, the 10-mg dose was deemed superior to the 100-mg dose. Common adverse events, including decreased appetite, cytokine-release syndrome, and pyrexia, were significantly less frequent in the 10-mg dose group.
The phase 2 clinical trial enrolled 220 patients previously diagnosed with small-cell lung cancer that had relapsed following initial platinum-based chemotherapy, with approximately 95% of these patients experiencing metastasis. Participants were randomly assigned to receive two doses of Tarlatamab - 10 mg versus 100 mg - administered intravenously every two weeks. After a median 10-month follow-up period, researchers observed a tumor size reduction in around 40% of patients, with an estimated 9-month survival rate of approximately 65%. Comparing the two doses, there was little difference in effectiveness, but considering safety, the 10-mg dose was deemed superior to the 100-mg dose. Common adverse events, including decreased appetite, cytokine-release syndrome, and pyrexia, were significantly less frequent in the 10-mg dose group.